Analysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), 4D Molecular Therapeutics (FDMT) and Cullinan Management (CGEM)

TipRanksAug 13 12:20 ET · Ratings

Buy Rating Affirmed for 4D Molecular Therapeutics Amidst Strong Financials and Promising Pipeline

TipRanksAug 12 18:45 ET · Ratings

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswireAug 12 08:00 ET

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Simply Wall StAug 10 10:26 ET

4D Molecular Therapeutics Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Yahoo FinanceAug 10 10:02 ET

Express News | HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

BenzingaAug 9 17:28 ET